The invention discloses application of transthyretin (TTR) to the inhibition of ocular neovascularization and belongs to the field of biochemistry, molecular biology and medical science. The application finds out that mammal TTR is given and ocular new blood vessels in STZ (Streptozocin)-induced diabetes mellitus rat and mouse models are obviously reduced. An in-vivo experiment model of ocular neovascularization and brain neovascularization verifies that the TTR has the effect of inhibiting the neovascularization and a result shows that the TTR acts on ocular capillary endothelial cells and can be used for effectively inhibiting the formation of 90 percent of the blood vessels; and when the TTR acts in the rat and mouse models, high up to 90% of neovascularization can be effectively inhibited.